PROGRAMME DAY 3

Wednesday 28 September 2022

08:30 - 10:00 08:30 - 09:00 09:00 - 09:30 09:30 - 10:00	**Plenary Session 3 | Main Auditorium** Co-chair: Rebecca Cox, University of Bergen, Norway Co-chair: David Wentworth, Centers for Disease Control and Prevention, USA Novel Insights in the Antigenic Drift of Influenza Virus HA and NA Ron Fouchier, Erasmus MC, Netherlands Impact of secretory IgA antibodies on prevention of influenza virus infection Hideki Hasegawa, WHO Collaborating Centre for Reference and Research on Influenza, Japan Looking Below the Surface - Influenza and COVID-19 in Africa Cheryl Cohen, University of the Witwatersrand, South Africa		
10:00 -10:30	Tea break | Hall 1		
	Virology & Pathogenesis HALL 1A	**Clinical Sciences & Vaccinology** THE STUDIO	**Public Health & Policy** MAIN AUDITORIUM
10:30 -12:00	**Influenza: Transmission**	**COVID-19 Vaccine [focus: vaccines in use, late-stage development and pancoronavirus vaccines]**	**Burden of Disease for Influenza and Dual Epidemics**
	Co-chair: Jessica Belser, Centers for Disease Control and Prevention, USA Co-chair: Sander Herfst, Erasmus, Netherlands	Co-chair: Rebecca Cox, University of Bergen, Norway Co-chair: Ian Wilson, The Scripps Research Institute, USA	Co-chair: Danielle Iuliano, Centers for Disease Control and Prevention, USA Co-chair: David Muscatello, University of New South Wales, Australia
10:35 - 11:00	Retooling the Ferret Model of Influenza Virus Transmission to Mimic Real World Scenarios Seema Lakdawala Emory University, USA	Breaking the Cycle: Toward a Preemptive Strategy for Future Coronavirus Vaccine Development Kayvon Modjarrad Pfizer, Inc., USA	The changing landscape of influenza burden in the time of COVID-19 David Muscatello University of New South Wales, Australia
11:00 - 11:12	A naturally occurring HA stabilizing amino acid (HA1-Y17) in a low pathogenic influenza A A(H9N2) virus contributes to virus airborne transmission [AOXI0116] Xiangjie Sun, Centers for Disease Control and Prevention, USA	Development of a bivalent vaccine against SARS-CoV-2 and influenza using a live attenuated influenza vaccine platform [AOXI0238] Irina Isakova-Sivak, Institute of Experimental Medicine, Russian Federation	Excess mortality from influenza and RSV during the COVID19 pandemic in the US: a natural experiment to clarify the etiology of respiratory deaths [AOXI0207] Chelsea Hansen, Fogarty International Center, USA
11:12 - 11:24	The Mechanisms of Hemagglutinin and Neuraminidase Adaptation in the Emergence of the 1968 H3N2 Pandemic Virus [AOXI0477] Jie Zhou, Imperial College London, UK	Non-neutralizing antibodies provide protection against lethal challenge with SARS-CoV-2 in murine and hamster infection models [AOXI00634] Jordan Clark, The Ichan School of Medicine at Mount Sinai, USA	Incidence of respiratory virus illness and hospitalizations in a Panama and El Salvador birth cohort, 2014-2018 [AOXI0639] Eduardo Azziz-Baumgartner, Centers for Disease Control and Prevention, USA
11:24 - 11:36	Epidemiology and molecular analyses of Influenza B viruses in Senegal from 2010 to 2019 [AOXI0185] Ndongo Dia, Institut Pasteur Dakar, Senegal	Determinants of humoral immune responses against antigenically distinct SARS-CoV-2 variants in COVID-19 vaccine breakthrough infection [AOXI0166] Sho Miyamoto, National Institute of Infectious Diseases, Japan	Impact of heterotypic and heterosubtypic repeat influenza infection patterns in a pediatric cohort in Managua, Nicaragua [AOXI0231] Aubree Gordon, University of Michigan, USA
11:36 - 11:48	Impact of acidic pH in respiratory aerosol on the inactivation times of influenza and coronaviruses [AOXI0199] Irina Glas, University of Zurich, Switzerland	Correlates of protection for the BNT162b2 vaccine three and four booster doses during an Omicron outbreak in a healthcare workers multi-center prospective study [AOXI0620] Tomer Hertz, Ben Gurion University of the Negev, Israel	Effects of Stacking Influenza Risk Factors on Odds of Influenza-Related Hospitalization [AOXI0245] Ian McGovern, Seqirus, USA
11:48 - 12:00	Pathogenesis and infection dynamics of high pathogenicity avian influenza virus (HPAIV) H5N6 (Clade 2.3.4.4b) in pheasants and onward transmission to chickens [AOXI0281] Yuan Liang, University of Copenhagan, Denmark	The receptor binding domain as a target for variant proof and pan-sarbecovirus vaccines [AOXI0377] George Carnell, University of Cambridge, UK	The contribution of influenza to ischemic heart disease mortality worldwide [AOXI0216] Sandra Chaves, Sanofi Vaccines, Belgium
12:00- 14:00	Lunch Hall 1		
12:30 - 13:30 HALL 1A	**Active and Passive Immunoprophylaxis: Lessons from Flu and Recent Innovations to Protect Vulnerable Patients** Sponsored by AstraZeneca 12:30 - 12:55 Influenza (flu) and SARS-CoV-2: successes and challenges | Albert Osterhaus (Chairperson), University of Veterinary Medicine, The Netherlands 12:55 - 13:15 Passive Immunoprophylaxis: Strategies for the Management of Respiratory Infections | Andrew Ustianowski, North Manchester General Hospital, UK 13:15 - 13:30 Q&A facilitated by Chairperson | All		
14:00 - 15:30	**Influenza - Innate Immune Response to Infection** HALL 1A	**Influenza: Antivirals and Therapeutics** THE STUDIO	**Pandemic Preparedness and Response I** MAIN AUDITORIUM
	Co-chair: Ryan Langlois, University of Minnesota, USA Co-chair: Andrew Mehle, University of Wisconsin - Madison, USA	Co-chair: Deb Fuller, University of Washington, USA Co-chair: Christopher Chiu, Imperial College London, UK	Co-chair: Joe Bresee, Taskforce for Global Health, USA Co-chair: Marie Mazur, Ready2Respond, USA
14:05 - 14:30	Integrin-Mediated Regulation of Epithelial Immunity During Influenza Infection Stacey Schultz-Cherry St. Jude Children's Research Hospital, USA	A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness Matteo Samuele Pizzuto Humabs BioMed, Switzerland	Reflections from two pandemics: vaccine demand forecasting as a key capability to enhance pandemic preparedness Marie Mazur Ready2Respond, USA

14:30 - 14:42	Sensing of self DNA amplifies innate immune responses to suppress influenza virus replication [AOXI0286] Andrew Mehle, University of Wisconsin Madison, USA	Fitness, transmission, and mechanism of baloxavir resistance of influenza A viruses with PA E23X substitutions [AOXI077] Jeremy Jones, St. Jude Children's Research Hospital, USA	The COVID-19 Scenario Modeling Hub: a multi-model effort to generate pandemic projections in the United States [AOXI0518] Cecile Viboud, Fogarty International Center, USA
14:42 - 14:54	Lung epithelial cell injury increases resistance to influenza virus infection in a type I interferon-dependent manner [AOXI0028] Sang-Uk Seo, The Catholic University of Korea, Republic of Korea	Broadly-neutralizing antibodies that bind to the hemagglutinin stalk domain enhance the effectiveness of neuraminidase inhibitors via Fc-mediated effector functions [AOXI0536] Ali Zhang, McMaster University, Canada	Classification of different pandemic COVID-19-periods in Germany based on parameters from the Pandemic Influenza Severity Assessment Tool (PISA) [AOXI0221] Kristin Tolksdorf, Robert Koch Institute, Germany
14:54 - 15:06	Release of influenza A virus vRNPs by macrophages during abortive infection may shape innate responses [AOXI0327] Sarah Londrigan, University of Melbourne, Australia	Design of Ligand-Targeted Immunotherapy for the Treatment of Influenza Virus Infections [AOXI0649] Imrul Shahriar, Eradivir, Inc., USA	Comparison Between Online and Face-to-face Health Education Approach for School Students of Hong Kong During the COVID-19 Pandemic Era [AOXI0553] Yiyang Guo, University of Hong Kong, Hong Kong
15:06 - 15:18	Integrated drivers of basal immunity and acute responses to influenza infection in diverse human populations [AOXI0645] Aisha Souquette, St. Jude Children's Research Hospital, USA	1,3-Diphenylurea derivatives inhibit the cellular entry of influenza A virus and SARS-CoV-2 [AOXI0581] Nirmal Kumar, Indian Institute of Science Education and Research, Mohali, India	Using high-resolution social contact networks to evaluate SARS-CoV-2 transmission and control in large-scale multi-day events [AOXI0106] Rachael Pung, London School of Hygiene and Tropical Medicine, UK
15:18 - 15:30	Analysis of mucosal innate immune responses to human and swine adapted influenza A viruses using swab samples [AOXI0173] Helena Aagaard Glud, Technical University of Denmark, Denmark	Rapid Detection of Influenza Outbreaks in Long Term Care Facilities Reduces Emergency Room Visits and Hospitalization: Rapid Assessment of, and Prophylaxis for Influenza for Denizens of Long-Term Care Facilities (RAPID-LTCF) [AOXI0145] Jonathan Temte, University of Wisconsin School of Medicine and Public Health, USA	Daily Antigen Rapid Testing Surveillance (DARTS) System for COVID-19 - a large-scale ad-hoc participatory community surveillance initiative using self-performed lateral flow rapid antigen tests in Hong Kong [AOXI0569] Hau Chi So, University of Hong Kong, Hong Kong
15:30 - 16:00	Tea break | Hall 1		
16:00 - 17:30	**Influenza - Adaptive Immune Response to Infection** **HALL 1A**	**COVID-19: Antivirals and Therapeutics** **THE STUDIO**	**Pandemic Preparedness and Response II** **MAIN AUDITORIUM**
	Co-chair: Sophie Valkenburg, University of Melbourne, Australia Co-chair: Tomer Hertz, Ben Gurion University of the Negev, Israel	Co-chair: Maria Zambon, Health Security Agency, UK Co-chair: Aeron Hurt, Roche, Switzerland	Co-chair: Vivien Dugan, Centers for Disease Control and Prevention, USA Co-chair: Wenqing Zhang, World Health Organization, Switzerland
16:05 - 16:30	**Influenza virus-specific CD8+ T cells across the human lifespan: a suboptimal reset for the elderly** Carolien van de Sandt University of Melbourne, Australia	**An overview of COVID-19 antivirals and therapeutics** Aeron Hurt Roche, Switzerland	
16:06 - 16:18			Current efforts to prepare for the future respiratory pandemics: understanding public health and social measures [AOXI0017] Ryoko Takahashi, World Health Organization, Switzerland
16:18 - 16:30			Enhancing Pandemic Preparedness - Understanding Global Population Needs for Pandemic Influenza Products [AOXI0011] Ioana Ghiga, World Health Organization, Switzerland
16:30 - 16:42	Increasing HbA1c levels reduces the CD8 T cell response to influenza virus in a TCR-dependent manner in individuals with diabetes mellitus [AOXI0277] Katina Hulme, University of Queensland, Australia	Risk Factors for persistent COVID infection in the immunocompromised host [AOXI0643] Mirella Salvatore, Weill Cornell Medical College, USA	Exploring determinants of response-ready influenza vaccination programs in five middle-income countries [AOXI0455] Marissa Malchione, Sabin Vaccine Institute, USA
16:42 - 16:54	Revealing epitope hierarchies in human polyclonal antibody responses to antigenically drifting seasonal influenza A viruses [AOXI0435] Julianna Han, The Scripps Research Institute, USA	A natural broad-spectrum inhibitor of enveloped virus entry, restricts SARS-CoV-2 and Influenza A Virus in preclinical animal models [AOXI0155] Rohan Narayan, Indian Institute of Science, India	A framework for seroepidemiologic investigations in pandemics: insights from an evaluation of WHO's COVID-19 Unity Studies initiative [AOXI276] Isabel Bergeri, WHO, Switzerland
16:54 - 17:06	Low glycan occupancy of N-linked glycosylation sites on hemagglutinin is sufficient to divert adaptive immune responses to A(H3N2) influenza virus [AIOXI0008] Irina Alymova, Centers for Disease Control and Prevention, USA	Safety, pharmacokinetics and anti-drug antibodies following a second dose of AZD7442 (tixagevimab/cilgavimab): open-label sub study of the PROVENT Phase 3 trial for symptomatic COVID 19 prevention [AOXI0494] Andrew Ustianowski, North Manchester General Hospital, UK	Enhancing Influenza Surveillance through Cloud Computing Platforms [AOXI0084] Peter Daly, Centers for Disease Control and Prevention, USA
17:06 - 17:18	Influenza virus infection induces high levels of CD52 expression on effector CD8 T cells in the infected lung [AOXI0268] So Young Chang, University of Melbourne, Australia	Analysis for specificity of SARS-CoV-2 viral titer testing in Ph2a and Ph2b part of ensitrelvir clinical study [AOXI0367] Keiko Baba, Shionogi & Co., Ltd, Japan	Building a COVID Biobank in response to the Pandemic by repurposing residual primary samples [AOXI0107] Rehana Jauhangeer, UKHSA, UK
17:18 - 17:30	Influenza ADCC-antibody responses in seasonal vaccination and pandemic infection of children as a correlate of protection [AOXI0024] Sophie Valkenburg, University of Melbourne, Australia	Efficacy of therapeutic monoclonal antibodies and antiviral drugs against SARS-CoV-2 variants [AOXI0418] Emi Takashita, National Institute of Infectious Diseases, Japan	Development of an RNA strand-specific hybridization assay to differentiate replicating versus non-replicating influenza A virus [AOXI0252] Patrick Yang, Centers for Disease Control and Prevention, USA
17:30 - 19:00	POSTER SESSION 3 | Refreshments | HALL 1		
18:00 - 19:00 THE STUDIO	**Progress in Influenza: Exploring the Potential of mRNA Science in Future Vaccine Strategy** Sponsored by Moderna 18:00 - 18:05 Welcome and Introduction | Chair: Allison McGeer, University of Toronto, Canada 18:05 - 18:20 Current Epidemiology of Seasonal Influenza and Major Challenges | Colin Russell, Amsterdam University Medical Center, The Netherlands 18:20 - 18:35 Beyond Hemagglutinin: A Focus on Neuramindasean and its role in Seasonal Influenza Vaccines | Ron Fouchier, Erasmus University, The Netherlands 18:35 - 18:50 mRNA Platform Technology | Raffael Nachbagauer, Moderna Inc., Cambridge, MA, USA 18:50 - 19:00 Discussion and Q&A		